Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Natixis

Natixis lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.9% during the fourth quarter, Holdings Channel reports. The firm owned 50,557 shares of the medical equipment provider’s stock after acquiring an additional 463 shares during the quarter. Natixis’ holdings in Intuitive Surgical were worth $26,389,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Atala Financial Inc purchased a new stake in Intuitive Surgical in the fourth quarter valued at approximately $25,000. Berbice Capital Management LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at $26,000. BankPlus Trust Department purchased a new stake in Intuitive Surgical in the 4th quarter valued at $28,000. Hurley Capital LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth $28,000. Finally, Summit Securities Group LLC purchased a new position in Intuitive Surgical during the 4th quarter worth $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $482.74 on Friday. The firm has a market capitalization of $171.94 billion, a price-to-earnings ratio of 75.31, a price-to-earnings-growth ratio of 5.85 and a beta of 1.55. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The stock’s fifty day moving average is $522.23 and its two-hundred day moving average is $532.02.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of research reports. Royal Bank of Canada upped their target price on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Raymond James increased their price objective on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Piper Sandler reissued an “overweight” rating and issued a $670.00 target price (up previously from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. BTIG Research set a $560.00 price target on Intuitive Surgical and gave the stock a “buy” rating in a report on Monday. Finally, Barclays boosted their price objective on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $611.81.

Insider Activity at Intuitive Surgical

In other news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total value of $53,684.34. Following the sale, the chief financial officer now directly owns 2,630 shares in the company, valued at $1,502,019.30. This represents a 3.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Myriam Curet sold 408 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the sale, the executive vice president now directly owns 353 shares in the company, valued at approximately $208,181.75. The trade was a 53.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,754 shares of company stock valued at $17,691,621. Insiders own 0.70% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.